知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

291 条记录 (耗时 0.062 秒)

    B-GLUCURONIDASE PROTEINS HAVING PNEUMOCOCCAL CAPSULE DEGRADING ACTIVITY AND METHODS OF USE
    1.
    发明公开
    B-GLUCURONIDASE PROTEINS HAVING PNEUMOCOCCAL CAPSULE DEGRADING ACTIVITY AND METHODS OF USE 审中-公开

    公开(公告)号：US20230285519A1

    公开(公告)日：2023-09-14

    申请号：US18016511

    申请日：2021-07-16

    申请人： UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

    发明人： Fikri Y. Avci ,  Paeton Wantuch

    IPC分类号： A61K38/47 ,  C12N9/24 ,  A61P31/04

    CPC分类号： A61K38/47 ,  A61P31/04 ,  C12N9/2402 ,  C12Y302/01031

    摘要： The present disclosure includes catalytically active truncations of a protein, referred to as a PnSPase protein, that degrade the capsular polysaccharide of serotype 3 Streptococcus pneumoniae. The disclosure includes a genetically modified cell that includes a PnSPase protein of the present disclosure, and compositions that include the protein, the polynucleotide encoding the protein, the genetically modified cell, or a combination thereof. Also provided are methods for using a PnSPase protein of the present disclosure, including methods for contacting a S. pneumoniae having a type III capsular polysaccharide with a PnSPase protein, increasing deposition of at least one complement component on the surface of a S. pneumoniae, treating an infection in a subject, treating a symptom in a subject, decreasing colonization of a subject by S. pneumoniae, or a combination thereof.

    METHODS AND COMPOSITIONS USING KLOTHO VARIANT POLYPEPTIDES
    9.
    发明申请
    METHODS AND COMPOSITIONS USING KLOTHO VARIANT POLYPEPTIDES 审中-公开

    公开(公告)号：US20180037623A1

    公开(公告)日：2018-02-08

    申请号：US15532634

    申请日：2015-12-02

    申请人： Novartis AG

    发明人： Donglin GUO ,  Chikwendu IBEBUNJO

    IPC分类号： C07K14/50 ,  C12N15/62 ,  C12N9/24

    CPC分类号： C07K14/50 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/30 ,  C12N9/2402 ,  C12N15/62 ,  C12Y302/01031

    摘要： The present disclosure is directed to compositions and methods related to an alpha sKlotho variant or fragment, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795. The present disclosure also pertains to an alpha sKlotho polypeptide variant or fragment, having mutations at V563 and/or K795, wherein the polypeptide variant or fragment is full-length, or optionally 1 to up to about 20 amino acids have been deleted from the C-terminus. The present disclosure also pertains to fusion polypeptides comprising: (a) an alpha sKlotho, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795; (b) a linker; and (c) FGF23, optionally having a mutation at R179, C206 and/or C244, or (c) serum albumin.